• Regular Credit: 20% of the amount by which QREs for the year exceed a fixed “base amount” (based on your historical R&D spending and gross receipts). 

• Alternative Simplified Credit (ASC): 14% of QREs over 50% of the average QREs for the prior three tax years (or 6% if you had no QREs in that three-year window). 

• Regular Credit may be larger if you have substantial, consistent historical R&D (and thus a higher base amount). 

• ASC is simpler if you lack a multi-year R&D history or want streamlined calculations. Once you elect ASC, you’re locked in for five tax years. 

Yes. A “qualified small business” (≤ $5 M average gross receipts) can elect to offset up to $500,000 of its R&D credit against payroll taxes: 

• First up to $250,000 against the employer’s share of Social Security tax.

• Then up to $250,000 against the employer’s share of Medicare tax. 

Unused R&D credits can be carried back one year (to the immediately preceding tax year) and any remaining credit can be carried forward for up to 20 years; the carryback vs. carryforward treatment is determined on your timelyfiled return.  

• QREs generally include: 
  • Wages of employees directly conducting or supporting qualified research. 
  • Supplies used in experimentation (e.g., prototype materials). 
  • Contract research payments to outside parties (65% creditable unless the contract qualifies as a “pass-through”). 
  • Rental or lease costs of computers or equipment used in qualified research. 

Only research performed within the U.S. or its possessions counts. Costs for activities conducted outside these jurisdictions are excluded from QREs.

Keep contemporaneous records that clearly tie: 

• Projects: objectives, scope, budgets. 

• Activities: lab notebooks, test plans, design diagrams, or code repositories. 

• Personnel: time logs or project-allocation reports showing hours on qualified research. 

Consult a specialist to: 

1. Confirm which activities and costs qualify.
2. Choose and document your optimal credit method.
3. Structure contracts and allocations to maximize QRE treatment. 
4. Ensure you meet all IRS substantiation and filing requirements. 

For tax years beginning after December 31, 2024, OBBBA adds $ 174A, under which taxpayers may elect to: 

• Immediately expense domestic R&E costs in the year incurred, or .

• Capitalize and amortize those domestic costs over 60 months (mid-year convention).
  
  Foreign R&E expenditures remain ineligible for expensing and must continue to be amortized over 180 months (15 years).

No. Because your 2024 year began January 1, 2024—before $ 174A’s effective date—your original 2024 return cannot use the new expensing election. You must capitalize and amortize 2024 R&E costs under the pre-OBBBA $ 174 rules (5 years domestic; 15 years foreign). 

Any trade or business incurring domestic R&E costs in a tax year beginning after December 31, 2024, may elect immediate expensing. There is no gross-receipts limit on the election itself. 

• Original return: Attach a written election statement by the return due date (including extensions) for the year the costs are incurred. 

• Amended-return relief: OBBBA provides a one-time window to amend 2022–2024 returns and retroactively elect expensing.
  Your statement must: 

• Cite “Election under $ 174A, Internal Revenue Code (One Big Beautiful Bill Amended).” 

• Identify the taxpayer name/EIN and tax year. 

• State the total domestic R&E amount elected for immediate expensing. 

• Briefly describe the nature of the costs (e.g., wages for Project X experimentation; prototype materials).
  
  Attach this to Form 1120 (C Corps) or the applicable flow-through return (1065, 1120-S, or Schedule 1/1040). Retain a copy plus supporting docs (time logs, invoices, project plans). Once filed, the election is irrevocable for that year. 

The $ 174A election only changes how you deduct or amortize R&E costs for income-tax purposes; it does not alter how you compute or claim the § 41 R&D credit, which remains based on QREs under the four-part test.